BioCentury | Jan 24, 2020
Finance

iOnctura taps European syndicate for series A to bring two ‘best-in-class’ programs to the clinic

On the strength of its new €15 million ($16.6 million) series A round, iOnctura believes it can have two best-in-class oncology candidates in the clinic within a year. Created in 2017 by former Merck KGaA...
BC Innovations | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer INDICATION: Lung cancer, pancreatic cancer UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in...
BC Innovations | Dec 19, 2018
Distillery Therapeutics

Inflammation; pulmonary

INDICATION: Asthma; pulmonary fibrosis Mouse studies suggest an inhaled prodrug of a PI3K inhibitor could help treat asthma and pulmonary fibrosis. In mouse models of acute allergic asthma and chronic asthma, inhalation of a methylbenzoate-based...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BC Week In Review | Sep 15, 2017
Clinical News

FDA approves Bayer’s PI3K inhibitor for follicular lymphoma

FDA granted accelerated approval to an NDA from Bayer AG (Xetra:BAYN) for Aliqopa copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer told BioCentury Aliqopa will be available immediately...
BC Extra | Sep 14, 2017
Company News

FDA approves Bayer’s PI3K inhibitor for follicular lymphoma

FDA granted accelerated approval to an NDA from Bayer AG (Xetra:BAYN) for Aliqopa copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer told BioCentury Aliqopa will be available immediately...
BC Week In Review | Jun 15, 2017
Clinical News

Bayer reports Phase II data for PI3K inhibitor copanlisib in DLBCL

Bayer AG (Xetra:BAYN) reported data from a Phase II trial in 67 patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who received ≥1 prior therapy showing that 60 mg IV copanlisib (BAY...
BC Innovations | Jun 7, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest jointly inhibiting PI3K and either PIM2 , TACC1 , ZAK , ZFR or ZNF565 could help treat breast cancer. An shRNA screen in a human breast cancer cell line...
BC Week In Review | May 19, 2017
Clinical News

Priority Review for Bayer's PI3K in follicular lymphoma

FDA accepted and granted Priority Review to an NDA from Bayer AG (Xetra:BAYN) for copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer expects a decision within six months....
Items per page:
1 - 10 of 13